Cybin
Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.
Top Stages
2 past transactions
Small Pharma
Acquisition in 2023
Small Pharma Ltd. is a pharmaceutical company based in London, United Kingdom, founded in 2015. The company specializes in developing a rapid-acting antidepressant aimed at treating patients with depression. Small Pharma employs a scalable model of outsourced drug development, leveraging expert intellectual property design to facilitate the transition from academic discovery to commercial products. By assembling specialized teams with proven expertise across essential development disciplines, Small Pharma aims to effectively execute its drug development programs.
Adelia Therapeutics
Acquisition in 2020
Adelia Therapeutics is a biopharmaceutical company based in Fitchburg, Massachusetts, incorporated in 2020. It specializes in developing a drug discovery platform focused on creating proprietary tryptamine-based therapeutics to address central nervous system (CNS) disorders. The company's initial target is treatment-resistant depression (TRD), with a goal of improving dosing efficacy and therapeutic indices through its innovative approach.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.